Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Minnesota
With
National Cancer Institute (NCI)
This second study under "Oral Tobacco as a Harm Reduction Product" grant is a clinical trial. Subjects will be randomized to the brand of smokeless tobacco that is determined to be most effective in Study 1 or to nicotine gum for 12 weeks to compare complete substitution for smoking. The secondary aims are to determine the effects of the products on biomarkers of exposure and toxicity. Other secondary aim includes examining the effects of the two products on withdrawal symptoms. Two sites will be used for these studies: University of Minnesota and Oregon Research Institute (ORI).
Age
18–70
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
smoking at least 10 cigarettes daily for the past year,
in good physical health (no unstable medical condition;
no contraindications for medicinal nicotine, as appropriate for the study, stable, good mental health (e.g., no recent unstable or untreated psychiatric diagnosis, including substance abuse, as determined by the DSM-IV criteria).
You may not be if
Subjects must not be currently using other tobacco or nicotine products; Female subjects cannot be pregnant or nursing.
Clareo Health | Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine
